| |||
---|---|---|---|
+... |
1938 in science |
---|
Fields |
Technology |
Social sciences |
Paleontology |
Extraterrestrial environment |
Terrestrial environment |
Other/related |
The year 1938 in science and technology involved some significant events, listed below.
Konrad Ernst Otto Zuse was a German civil engineer, pioneering computer scientist, inventor and businessman. His greatest achievement was the world's first programmable computer; the functional program-controlled Turing-complete Z3 became operational in May 1941. Thanks to this machine and its predecessors, Zuse is regarded by some as the inventor and father of the modern computer.
Cystic fibrosis (CF) is a rare genetic disorder that affects mostly the lungs, but also the pancreas, liver, kidneys, and intestine. The hallmark feature of CF is the accumulation of thick mucus in different organs. Long-term issues include difficulty breathing and coughing up mucus as a result of frequent lung infections. Other signs and symptoms may include sinus infections, poor growth, fatty stool, clubbing of the fingers and toes, and infertility in most males. Different people may have different degrees of symptoms.
The Z3 was a German electromechanical computer designed by Konrad Zuse in 1938, and completed in 1941. It was the world's first working programmable, fully automatic digital computer. The Z3 was built with 2,600 relays, implementing a 22-bit word length that operated at a clock frequency of about 5–10 Hz. Program code was stored on punched film. Initial values were entered manually.
The year 1940 in science and technology involved some significant events, listed below.
The year 1912 in science and technology involved some significant events, listed below.
The Weizmann Institute of Science is a public research university in Rehovot, Israel, established in 1934, 14 years before the State of Israel. It differs from other Israeli universities in that it offers postgraduate-only degrees in the natural and exact sciences.
The year 1937 in science and technology involved some significant events, listed below.
The year 1954 in science and technology involved some significant events, listed below.
Patent ductus arteriosus (PDA) is a medical condition in which the ductus arteriosus fails to close after birth: this allows a portion of oxygenated blood from the left heart to flow back to the lungs through the aorta, which has a higher blood pressure, to the pulmonary artery, which has a lower blood pressure. Symptoms are uncommon at birth and shortly thereafter, but later in the first year of life there is often the onset of an increased work of breathing and failure to gain weight at a normal rate. With time, an uncorrected PDA usually leads to pulmonary hypertension followed by right-sided heart failure.
The year 1989 in science and technology involved many significant events, some listed below.
The year 1952 in science and technology involved some significant events, listed below.
The year 1941 in science and technology involved some significant events, listed below.
The year 1936 in science and technology involved some significant events, listed below.
In the fetus, the ductus venosus shunts a portion of umbilical vein blood flow directly to the inferior vena cava. Thus, it allows oxygenated blood from the placenta to bypass the liver. Compared to the 50% shunting of umbilical blood through the ductus venosus found in animal experiments, the degree of shunting in the human fetus under physiological conditions is considerably less, 30% at 20 weeks, which decreases to 18% at 32 weeks, suggesting a higher priority of the fetal liver than previously realized. In conjunction with the other fetal shunts, the foramen ovale and ductus arteriosus, it plays a critical role in preferentially shunting oxygenated blood to the fetal brain. It is a part of fetal circulation.
Dorothy Hansine Andersen was an American physician, pediatrician, and pathologist who first identified cystic fibrosis. She was the first to describe the disease, and name it. In 1939, she was awarded the E. Mead Johnson Award for her identification of the disease. In 2002, she was inducted into the National Women's Hall of Fame.
Interrupted aortic arch is a very rare heart defect in which the aorta is not completely developed. There is a gap between the ascending and descending thoracic aorta. In a sense it is the complete form of a coarctation of the aorta. Almost all patients also have other cardiac anomalies, including a ventricular septal defect (VSD), aorto-pulmonary window, and truncus arteriosus. There are three types of interrupted aortic arch, with type B being the most common. Interrupted aortic arch is often associated with DiGeorge syndrome.
Sir John Fraser, 1st Baronet, was Regius Professor of Clinical Surgery at Edinburgh University from 1925 to 1944 and served as principal of the University of Edinburgh from 1944 to 1947.
Agustín Walfredo Castellanos was a physician. Castellanos obtained his Medical Degree from the University of Havana School of Medicine in 1925. He was a pediatrician, radiologist and cardiologist who was a pioneer in the field of angiocardiography.
Char syndrome is an autosomal dominant congenital disease caused by mutations in TFAP2B gene which affects the development of the bones of the face as well as the heart and limbs. During embryo development, TFAP2B regulates the production of the protein AP-2β, a transcription factor that is active in the neural crest and helps regulate genes that control cell division and apoptosis. There are at least 10 mutations of this gene that have been identified in people presenting Char syndrome, which alters specific regions of the gene preventing production of the transcription factor and disrupting normal development of embryo structures. People with this condition present a very distinct facial appearance with flattened cheek bones, flat and broad tip nose, shortened distance between the nose and upper lip, triangular-shaped mouth with tick lips and strabismus. It is also characterized by a patent ductus arteriosus, which is the failure to close the ductus that connects the aorta and pulmonary artery during pre-birth life and may cause many symptoms including breathing issues and heart failure. Abnormalities of hand and finger development have also been reported in people with this condition, including short or absent fifth finger. Other abnormal findings include supernumerary nipples. These conditions often affect multiple members of a family and there are no reports of non-genetic factors that might be related with incidence of this syndrome. It was first described by Florence Char in 1978.
Peter Grootenhuis was a Dutch-American Medicinal Chemist. Grootenhuis was the Project Leader and Co-Inventor of Ivacaftor (VX-770), the first CFTR potentiator FDA approved drug to treat the underlying cause of Cystic Fibrosis (CF) in patients with certain mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene, who account for 4-5% of CF cases. Grootenhuis also led the Vertex team to subsequent discovery of Orkambi, the combination of Ivacaftor and Lumacaftor(VX-809), approved to treat CF in people with two copies of the F508del mutation. Most recently, Grootenhuis's team discovered Tezacaftor (VX-661) and Elexacaftor (VX-445), which in combination with Ivacaftor are the components of Trikafta, a drug approved by the FDA in 2019 to treat CF in more than 90% of CF patients. For Grootenhuis’ contributions to the discovery of these compounds, he was awarded the 2018 IUPAC Richter Prize, the American Chemical Society’s 2013 Heroes of Chemistry Award, and inducted into the American Chemical Society Division of Medicinal Chemistry Hall of Fame. Grootenhuis has contributed to the discovery of over 11 clinical candidates, co-authored more than 100 peer reviewed papers and is inventor of 65 + U.S Patents, and more than 50 EU Patents.